{
  "emaEpar": [
    {
      "activeSubstance": "ibritumomab tiuxetan",
      "conditionIndication": "Zevalin is indicated in adults.[90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established.[90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL).",
      "inn": "ibritumomab tiuxetan",
      "marketingAuthorisationDate": "2004-01-16 01:00:00",
      "marketingAuthorisationHolder": "Ceft Biopharma s.r.o.",
      "medicineName": "Zevalin",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin"
    }
  ],
  "fdaDrugLabel": [],
  "id": "Ibritumomab_Tiuxetan",
  "nciThesaurus": {
    "casRegistry": "206181-63-7",
    "chebiId": "",
    "chemicalFormula": "C23H32N5O10S",
    "definition": "An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.",
    "fdaUniiCode": "4Q52C550XK",
    "identifier": "C29981",
    "preferredName": "Ibritumomab Tiuxetan",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1512",
      "C164034"
    ],
    "synonyms": [
      "IBRITUMOMAB TIUXETAN",
      "IDEC-129",
      "IDEC-2B8",
      "Ibritumomab Tiuxetan",
      "Zevalin",
      "ibritumomab tiuxetan"
    ]
  }
}